Literature DB >> 16342172

EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements.

Bruce Poppe1, Nicole Dastugue, Jo Vandesompele, Barbara Cauwelier, Betty De Smet, Nurten Yigit, Anne De Paepe, Jose Cervera, Christian Recher, Véronique De Mas, Anne Hagemeijer, Frank Speleman.   

Abstract

In contrast to the well-documented involvement of EVI1 in various 3q26 aberrations, the transcriptional status of EVI1 in rare recurrent or sporadic 3q26 chromosomal defects has remained largely unexplored. Moreover, in a recent report, the association between 3q26 alterations in myeloid proliferations and ectopic EVI1 expression was questioned. Therefore, we performed a detailed physical mapping of 3q26 breakpoints using a 1.3-Mb tiling path BAC contig covering the EVI1 locus and a carefully designed quantification of both EVI1 and MDS/EVI1 transcripts in 30 hematological malignancies displaying 3q26 aberrations. Cases included well-known rare, recurring chromosomal aberrations such as t(3;17)(q26;q22), t(2;3)(p21-22;q26), and t(3;6)(q26;q25), as well as 10 new sporadic cases. Extensive 3q26 breakpoint mapping allowed unequivocal and sensitive FISH detection of EVI1 rearrangements on both metaphases and interphase nuclei. Real-time quantitative PCR analyses indicated that typically both MDS1/EVI1 and EVI1, but not MDS1, were expressed in these malignancies, with EVI1 the primary transcript. In conclusion, we have demonstrated EVI1 involvement in numerous novel sporadic and recurrent 3q26 rearrangements. Our results underscore the feasibility of FISH as an adjunct to PCR for the identification of EVI1 deranged leukemias and identified EVI1 as the principal transcript expressed in these malignancies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16342172     DOI: 10.1002/gcc.20295

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  12 in total

1.  Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.

Authors:  Iria Vázquez; Miren Maicas; José Cervera; Xabier Agirre; Oskar Marin-Béjar; Nerea Marcotegui; Carmen Vicente; Idoya Lahortiga; Maria Gomez-Benito; Claudia Carranza; Ana Valencia; Salut Brunet; Eva Lumbreras; Felipe Prosper; María T Gómez-Casares; Jesús M Hernández-Rivas; María J Calasanz; Miguel A Sanz; Jorge Sierra; María D Odero
Journal:  Haematologica       Date:  2011-07-12       Impact factor: 9.941

Review 2.  Unraveling the molecular pathophysiology of myelodysplastic syndromes.

Authors:  Rafael Bejar; Ross Levine; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

3.  Overexpression of EVI1 interferes with cytokinesis and leads to accumulation of cells with supernumerary centrosomes in G0/1 phase.

Authors:  Kadin Karakaya; Friederike Herbst; Claudia Ball; Hanno Glimm; Alwin Krämer; Harald Löffler
Journal:  Cell Cycle       Date:  2012-08-16       Impact factor: 4.534

4.  Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.

Authors:  Heesun J Rogers; James W Vardiman; John Anastasi; Gordana Raca; Natasha M Savage; Athena M Cherry; Daniel Arber; Erika Moore; Jennifer J D Morrissette; Adam Bagg; Yen-Chun Liu; Susan Mathew; Attilio Orazi; Pei Lin; Sa A Wang; Carlos E Bueso-Ramos; Kathryn Foucar; Robert P Hasserjian; Ramon V Tiu; Matthew Karafa; Eric D Hsi
Journal:  Haematologica       Date:  2014-01-24       Impact factor: 9.941

5.  Zinc finger transcription factor ecotropic viral integration site 1 is induced by all-trans retinoic acid (ATRA) and acts as a dual modulator of the ATRA response.

Authors:  Sonja C Bingemann; Torsten A Konrad; Rotraud Wieser
Journal:  FEBS J       Date:  2009-10-16       Impact factor: 5.542

6.  Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes.

Authors:  Torsten A Konrad; Anna Karger; Hubert Hackl; Ilse Schwarzinger; Irene Herbacek; Rotraud Wieser
Journal:  J Leukoc Biol       Date:  2009-07-15       Impact factor: 4.962

7.  Identification of two critically deleted regions within chromosome segment 7q35-q36 in EVI1 deregulated myeloid leukemia cell lines.

Authors:  An De Weer; Bruce Poppe; Sarah Vergult; Pieter Van Vlierberghe; Marjan Petrick; Robrecht De Bock; Yves Benoit; Lucien Noens; Anne De Paepe; Nadine Van Roy; Björn Menten; Frank Speleman
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

8.  EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells.

Authors:  Anna Rommer; Birgit Steinmetz; Friederike Herbst; Hubert Hackl; Petra Heffeter; Daniela Heilos; Martin Filipits; Katarina Steinleitner; Shayda Hemmati; Irene Herbacek; Ilse Schwarzinger; Katharina Hartl; Pieter Rondou; Hanno Glimm; Kadin Karakaya; Alwin Krämer; Walter Berger; Rotraud Wieser
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

9.  Detection of RUNX1-MECOM fusion gene and t(3;21) in a very elderly patient having acute myeloid leukemia with myelodysplasia-related changes.

Authors:  John Jeongseok Yang; Sun Young Cho; Jin-Tae Suh; Hee Joo Lee; Woo-In Lee; Hwi-Joong Yoon; Sun Kyung Baek; Tae Sung Park
Journal:  Ann Lab Med       Date:  2012-08-13       Impact factor: 3.464

10.  EVI1 activation in blast crisis CML due to juxtaposition to the rare 17q22 partner region as part of a 4-way variant translocation t(9;22).

Authors:  An De Weer; Bruce Poppe; Barbara Cauwelier; Andre Carlier; Jan Dierick; Bruno Verhasselt; Jan Philippé; Nadine Van Roy; Frank Speleman
Journal:  BMC Cancer       Date:  2008-07-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.